Fundraising Fox

Albert J. Robichaud

Investor

Partner at Cure Ventures

Cambridge, Massachusetts, United States

About

Partner with over three decades in neuroscience drug discovery. Founding scientist and Chief Scientific Officer at Sage Therapeutics, contributing to approved CNS drugs Zulresso and Zurzuvae, with prior roles at Lundbeck and Wyeth.

Experience

  1. Tortugas NeurosciencePresident and Head of Research and Developmentcurrent2026 β€” present
  2. Cure VenturesVenture Partner2026
  3. Cure VenturesPartner2024 β€” 2026Boston, Massachusetts, United States
  4. 73 R&D ConsultingScientist2023 β€” 2024United States
  5. Sage TherapeuticsChief Scientific Officer2011 β€” 2023Cambridge, MA
  6. Lundbeck Research, USAVice President2010 β€” 2011
  7. Wyeth pharmaceuticalsSenior Director; Head of Princeton Chemistry Dept2002 β€” 2010
  8. Bristol-Myers SquibbDirector2001 β€” 2002
  9. DuPont PharmaceuticalsDirector1999 β€” 2001
  10. DuPont Merck PharmaDirector1997 β€” 1999
  11. Merck PharmaResearch Fellow1991 β€” 1997
  12. FMCStaff Chemist1982 β€” 1984

Education

  1. Colorado State UniversityPost Doctoral Fellow, Organic Chemistry1989 β€” 1991
  2. UC IrvinePhD, Organic Chemistry1984 β€” 1989
  3. Rensselaer Polytechnic InstituteB.S., Chemistry1978 β€” 1982

Skills & more

Medicinal Chemistry90Lead Change25Organic Chemistry61Drug Discovery53Neuroscience53Biotechnology18Biochemistry4ADME2Clinical Development4Chemistry26Analytical Chemistry2Assay Development3
+3 moreDrug DesignDrug DevelopmentHPLC

From Albert's professional profile.

Same school

Shared employers

Colleagues at Cure Ventures